Is pomalidomide included in medical insurance?

Pomalidomide (Pomalidomide), as a third-generation immunomodulator, has been officially launched in China and has been included in the National Reimbursement Directory for the treatment of relapsed or refractory multiple myeloma (MM). Its inclusion in medical insurance marks an important step in the protection of rare tumors and high-cost anti-cancer drugs in my country. Although drug prices are relatively high, the proportion of patients paying out-of-pocket after medical insurance reimbursement has been significantly reduced. The specific reimbursement proportions may vary slightly in different regions. Patients can consult local hospitals or medical insurance departments to confirm the latest policies.

Pomalidomide was developed by a well-known international pharmaceutical company and was first approved for marketing in Europe and the United States. It has attracted clinical attention for its strong anti-tumor activity and controllable adverse reactions. After entering the Chinese market, due to its key role in the treatment of multiple myeloma, it was quickly included in the priority review channel and approved for local production. After being covered by medical insurance, the financial pressure caused by long-term treatment of patients has been greatly alleviated, allowing more patients to receive continuous and standardized drug treatment.

Driven by medical insurance policies, the accessibility of pomalidomide continues to increase, which has also led to the optimization of domestic comprehensive treatment plans for multiple myeloma. Doctors often combine pomalidomide with dexamethasone or other targeted drugs to improve response rates and extend survival, depending on the patient's condition. In recent years, domestic and foreign scholars have also been exploring the potential application of pomalidomide in other malignant hematological diseases such as lymphoma, providing new directions for expanded research on the drug.

Overall, the inclusion of pomalidomide in medical insurance not only has practical clinical significance, but also reflects China’s policy support for the universalization of innovative anti-cancer drugs. In the future, with the gradual launch of generic drugs and the continued optimization of the medical insurance negotiation mechanism, the price of pomalidomide is expected to be further reduced, allowing more patients to benefit from this innovative immunomodulatory treatment.

Reference materials:https://en.wikipedia.org/wiki/Pomalidomide